RT Book, Section
A1 Lautner, Meeghan
A1 Parker, Catherine
A1 Bedrosian, Isabelle
A2 Morita, Shane Y.
A2 Balch, Charles M.
A2 Klimberg, V. Suzanne
A2 Pawlik, Timothy M.
A2 Posner, Mitchell C.
A2 Tanabe, Kenneth K.
SR Print(0)
ID 1145760451
T1 Breast Cancer Subtypes Identified by Gene Expression Profiles and Molecular Markers
T2 Textbook of Complex General Surgical Oncology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071793315
LK hemonc.mhmedical.com/content.aspx?aid=1145760451
RD 2023/03/27
AB In  2000,  the  era  of  genomic  medicine  in  breast  cancer  was  introduced  when  Perou  et  al1  identified  the  “molecular  portraits”  of  breast  cancer.  By  analyzing  the  gene  expression  patterns  of  8102  genes  from  65  breast  tumors,  these  authors  identified  four  broad  groups  of  tumors:  (i)  estrogen  receptor  (ER)  positive/luminal-like,  (ii)  basal-like,  (iii)  ErbB-2  positive,  and  (iv)  normal  breast.  These  subtypes  appeared  biologically  distinct  as  evidenced  by  their  distinct  genetic  makeups  and  clinically  distinct  as  evidenced  by  significant  differences  in  outcome  across  the  four  groups.  These  initial  subtypes  have  since  been  further  refined  by  a  number  of  groups,  including  The  Cancer  Genome  Atlas  Network,2  and  a  consensus  has  emerged  that  there  are  four  important  subtypes,  often  referred  to  as  luminal  A,  luminal  B,  HER2/neu  positive,  and  basal-like,  each  with  distinct  features  and  clinical  behavior.